NCT02395640View on ClinicalTrials.gov

The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

438

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

February 23, 2021

Study Completion Date

February 23, 2021

Conditions
Gastric Cancer
Interventions
DRUG

Epirubicin

50mg/m2 ivgtt d1

DRUG

Oxaliplatin

DRUG

Capecitabine

1000mg/m2 po d1-14

Trial Locations (1)

200032

Fudan University Cancer Hospital, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT02395640 - The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter